Stressgen granted U.S. patent providing coverage for the manufacture of HspE7

Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted US Patent Number 6,900,035, covering methods of manufacturing HspE7, the Company's lead product candidate for human papillomavirus (HPV)- related diseases and cancer.

This patent application extends the protection provided by the Company's original HspE7 US Patent Number 6,524,825 granted in 2003 and covering HPV fusion protein compositions.

"This manufacturing patent further strengthens our intellectual property estate surrounding HspE7, our lead product candidate, and any additional CoVal(TM) fusion proteins containing HPV antigens that may be constructed for the treatment of HPV-related diseases and cancer," said Gregory M. McKee, President and Chief Executive Officer of Stressgen. "We will continue to aggressively protect our intellectual property surrounding our CoVal(TM) fusion proteins, including patents covering our core technology platform and those covering the specific products in our pipeline."